



File / dossier : 6.01.07

Date: 2021-05-05

Edocs: 6556583

**Written submission from the
University of Alberta**

**Mémoire de
l'Université de l'Alberta**

In the Matter of the

À l'égard de

BWXT Medical Ltd.

BWXT Medical Ltd.

Application for a Class IB nuclear substance
processing facility operating licence

Demande pour un permis d'exploitation d'une
installation de traitement de substances
nucléaires de catégorie IB

Commission Public Hearing

Audience publique de la Commission

June 9-10, 2021

9 et 10 juin 2021

*Interim Chair***Frank Wuest, PhD, Dr.rer.nat.habil**

Tel: 780.432.8556

Fax: 780.432.8425

wuest@ualberta.ca

*Associate Chair, Education***Alan Underhill, PhD**

Tel: 780.577.8083

Fax: 780.432.8425

alan.underhill@ualberta.ca

*Assistant Chair, Administration***Yvette Labiuk**

Tel: 780.432.8576

Fax: 780.432.8425

yvette.labiuk@ualberta.ca

*Director, Experimental Oncology***Roseline Godbout, PhD**

Tel: 780.432.8901

Fax: 780.432.8892

rgodbout@ualberta.ca

*Director, Medical Oncology***Scott North, MD, FRCPC, MHPE**

Tel: 780.432.8221

Fax: 780.432.8888

snorth@ualberta.ca

*Director, Medical Physics***B. Gino Fallone, PhD, FCCPM, FAAPM, FCOMP**

Tel: 780.432.8750

Fax: 780.432.8615

bfallone@ualberta.ca

*Director, Oncologic Imaging***Frank Wuest, PhD, Dr.rer.nat.habil**

Tel: 780.989.8150

Fax: 780.432.8483

wuest@ualberta.ca

*Director, Palliative Care Medicine***Sharon Watanabe, MD, FRCPC**

Tel: 780.432.8266

Fax: 780.432.8419

watanabe@ualberta.ca

*Director, Radiation Oncology***Wilson Roa, MD, MSc, FRCPC**

Tel: 780.432.8755

Fax: 780.432.8380

wroa@ualberta.ca

*Director, Surgical Oncology***Todd McMullen, MD, PhD, FRCSC FACS**

Tel: 780.432.8337

Fax: 780.432.8333

todd.mcmullen@ualberta.ca

*Director, Radiation Therapy Degree Program***Susan Fawcett, MRT(T), BSc, MA**

Tel: 780.492.7975

Fax: 780.492.9531

susan.fawcett@ualberta.ca

Past Chairs

Dr. David Eisenstat, Professor & Chair, July 2017 – September 2020

Dr. AJB McEwan, Professor & Chair, July 1, 2007 – June 30, 2017

Dr. Carol Cass, Professor & Chair, July 1, 1996 – June 30, 2007 (Professor Emerita)

Dr. Anthony Fields, Associate Professor & Acting Chair, July 1, 1993 – June 30, 1996 (Professor Emeritus)

Edmonton, 14. April 2021

Senior Tribunal Officer, Secretariat
Canadian Nuclear Safety Commission

280 Slater Street

P.O. Box 1046, Station B

Ottawa, Ontario K1P 5S9

Email: cns.interventions.ccsn@canada.ca**Re: BWXT Medical Ltd. Application for a Class IB License (June 9-10 Public Hearing)**

Dear President and Commission Members,

My name is Dr. Frank Wuest and I am the Interim Chair of the Department of Oncology at the Cross Cancer Center in Edmonton, Alberta. My research interests are embedded in the multidisciplinary field of translational cancer research with a particular focus on imaging biomarkers. My research is aimed at the design, evaluation, and clinical translation of innovative radiopharmaceuticals to optimize cancer diagnosis and treatment.

I am providing this letter as means of intervening by written submission to the CNSC on behalf of BWXT Medical Ltd. who are currently seeking a 10-year Class 1B license for the Kanata Operations facility.

BWXT Medical is an experienced manufacturer and supplier of critical medical isotopes and radiopharmaceuticals for research, diagnostic and therapeutic uses. BWXT Medical's passion to deliver quality nuclear medicine is driven by our commitment to patient health. The new isotope programs that BWXT Medical Ltd. is currently developing will drive innovation and allow for the realization of new cancer therapies.

BWXT Medical's Kanata operations produces and supplies the following products:

- Indium-111 Oxyquinoline Solution: a diagnostic radiopharmaceutical used in the assessment of inflammation and infection. This helps in the assessment of inflammation and infection, for example diabetic foot.
- TheraSphere™ a sterile, active implantable Class III medical device used to treat liver cancer. BWXT Medical is under contract by Boston Scientific Corporation to supply this product.

BWXT Medical operates in one of the most highly regulated industries in the world and our operation must meet a wide variety of nuclear and health regulatory requirements. BWXT Medical is committed to meeting or exceeding all applicable regulatory requirements.

The Nuclear Medicine department at the Cross Cancer Center and the University Hospital uses several of the products currently manufactured by BWXT Medical in our routine clinical applications. In addition, I am actively pursuing opportunities to collaborate with BWXT to develop new Nuclear Medicine products.

It is important that BWXT Medical receive their 10-year Class 1B license from the CNSC to ensure that there is no disruption in the supply of current products and to ensure that new development programs remain on track.

Please feel free to reach out to me at any point in time.

Sincerely,

A handwritten signature in blue ink, appearing to read 'Frank Wuest', with a stylized flourish at the end.

Frank Wuest, PhD / *Dr. rer. nat. habil.*
Professor and Interim Chair, Department of Oncology
The Dianne and Irving Kipnes Chair in Radiopharmaceutical Sciences

Tel: (780) 391-7666

Fax: (780) 432-8483

E-mail: wuest@ualberta.ca